(Live Biotherapeutic Products – LBP)
The best Microbiome Therapeutics CDMO in the world does not treat live biotherapeutics like probiotics. It treats them as regulated, strain-defined, clinically controlled biological drugs built on fragile, living systems. Elise Biopharma is that Microbiome Therapeutics CDMO.
Elise Biopharma’s Microbiome Therapeutics CDMO Services are purpose-built for live biotherapeutic products (LBPs)—a rapidly expanding class of therapeutics that sit at the intersection of microbiology, immunology, metabolic engineering, and clinical medicine. These are not supplements. They are not consumer probiotics. They are strain-defined, mechanism-driven, clinically developed biological therapeutics that must meet regulatory, manufacturing, and analytical standards comparable to other advanced biologics.
Elise Biopharma builds LBP programmes with the level of control, discipline, and scientific precision this category demands. Live organisms introduce variables that do not exist in protein or nucleic acid manufacturing: viability, phenotypic drift, anaerobic sensitivity, metabolic variability, ecological interaction, and stability constraints that extend from fermentation through formulation, storage, and delivery. A weak provider treats these as complications. A true Microbiome Therapeutics CDMO treats them as the core of the process.
Our Microbiome Therapeutics CDMO Services are designed for:
- single-strain live biotherapeutics
- defined consortia
- engineered microbial therapeutics
- anaerobic gut commensals
- spore-forming therapeutic strains
- metabolite-producing strains
- next-generation probiotic-derived therapeutics
- microbiome-based immunomodulators
- oncology and metabolic disease microbiome platforms
This is why this page belongs in Platforms & Modalities. Microbiome therapeutics are not a subset of probiotics. They are a distinct modality with their own manufacturing logic, regulatory pathway, and scientific requirements. Elise Biopharma is built for that modality.
Why Microbiome Therapeutics Are Different
The most common mistake in the market is assuming microbiome therapeutics are an extension of probiotics. They are not.
Probiotics:
- consumer or nutraceutical positioning
- loosely defined strains
- minimal regulatory burden
- broad claims
Microbiome therapeutics (LBPs):
- strain-defined, often genome-characterised
- mechanism-driven
- clinically evaluated
- tightly controlled manufacturing
- full CMC and regulatory expectations
That difference changes everything.
A true Microbiome Therapeutics CDMO must manage:
- strain identity and genetic stability
- viability across process and shelf life
- anaerobic or microaerophilic sensitivity
- metabolic output consistency
- formulation survival
- dose accuracy in CFU or functional units
- host interaction implications
- regulatory-grade documentation
This is why microbiome therapeutics are one of the fastest-growing and most technically demanding areas in biomanufacturing. They must be handled as drug manufacturing, not generic fermentation.
Why Elise Biopharma
Elise Biopharma approaches LBPs as living pharmaceutical systems, not industrial microbes.
Our platform is built around five defining principles:
1. Strain fidelity is non-negotiable
We control identity, genotype, phenotype, and passage stability from early development through manufacturing.
2. Anaerobic precision is engineered, not assumed
Strict anaerobes are handled with controlled oxygen exclusion across upstream, downstream, and fill.
3. Viability is treated as a critical quality attribute
Not just survival, but functional viability aligned with therapeutic intent.
4. Manufacturing is aligned with clinical reality
Dose form, delivery route, and patient use are built into process design early.
5. Analytics define the product
Genomic, phenotypic, and metabolic data are used to define and control the therapeutic. This is the operating model required to move microbiome programmes from concept to clinic with credibility.
What We Build in Microbiome Therapeutics
Our Microbiome Therapeutics CDMO Services support a wide spectrum of LBP programmes:
Single-Strain Therapeutics
- defined commensal bacteria
- engineered strains
- metabolic-output-driven therapeutics
Multi-Strain Consortia
- rationally designed microbial communities
- functional redundancy and resilience design
- ecological stability considerations
Engineered Microbial Therapeutics
- synthetic biology-enabled strains
- pathway-modified organisms
- targeted metabolite production
Spore-Based Systems
- stability-enhanced delivery platforms
- oral dosing compatibility
- extended shelf-life strategies
Anaerobic Gut Microbiome Platforms
- strict anaerobes
- oxygen-sensitive strains
- gut-relevant metabolic systems
This diversity is exactly why a specialised Microbiome Therapeutics CDMO is required. Each class behaves differently in fermentation, recovery, formulation, and clinical use.
Niche Service Areas
In addition to core LBP development and GMP manufacturing, Elise Biopharma supports specialised niche services that many generalist CDMOs cannot handle well:
Strict Anaerobe Development
- oxygen-excluded process design
- anaerobic media optimisation
- redox-controlled fermentation strategies
- closed handling for highly sensitive strains
Defined Consortium Manufacturing
- strain-ratio control
- co-culture balancing
- selective loss risk assessment
- consortium composition analytics
Engineered Microbe CMC Support
- edit verification
- engineered pathway stability
- genotype-to-phenotype control strategies
- comparability frameworks for modified strains
Spore Therapeutics Development
- sporulation optimisation
- germination performance studies
- spore stability characterisation
- oral solid dose compatibility
Viability-Critical Formulation
- lyophilisation cycle development
- cryoprotectant and excipient screening
- enteric protection strategies
- encapsulation for targeted delivery
Functional Potency Assay Development
- metabolic activity assays
- host-relevant in vitro functional models
- mechanism-linked potency strategy
- release testing aligned with therapeutic intent
Low-Oxygen Fill and Finish Support
- controlled-atmosphere dispensing
- closed transfer strategies
- viability-preserving bulk handling
- packaging systems aligned to live product stability
Microbiome-Specific Stability Programmes
- CFU retention over time
- phenotype and metabolic consistency studies
- stress testing across temperature and humidity ranges
- shelf-life modelling for live products
These niche capabilities matter because microbiome programmes do not usually fail on concept alone. They fail at the interfaces between biology, process, formulation, and control.
Upstream Process Development
Upstream development in Microbiome Therapeutics CDMO Services is fundamentally different from traditional fermentation.
The process must account for:
- strict anaerobic conditions for many strains
- oxygen sensitivity thresholds
- nutrient specificity and metabolic pathways
- growth kinetics versus functional output
- metabolite accumulation and feedback inhibition
- pH and redox control
- co-culture dynamics for consortia
- strain dominance and stability
Key upstream capabilities include:
- anaerobic bioreactor systems
- gas-controlled fermentation environments
- strain-specific media development
- growth-versus-function optimisation
- co-culture balance control
- scale-down models for sensitive organisms
- robustness testing under process stress
Unlike protein systems, where the product is separate from the organism, here the organism is the product. That changes the entire process philosophy.
Elise Biopharma’s Microbiome Therapeutics CDMO Services treat upstream as both production and preservation of therapeutic identity.
Downstream Processing and Recovery
Downstream in microbiome therapeutics is not purification in the classical sense. It is controlled recovery of living biological systems.
Key considerations:
- maintaining viability
- preventing oxygen exposure
- preserving metabolic state
- removing unwanted media components
- concentration without damage
- stabilisation for formulation
Typical operations include:
- gentle biomass recovery
- centrifugation or filtration under controlled conditions
- cryoprotection strategies
- lyophilisation or spray drying, strain-dependent
- encapsulation or protective formulation
- stabilisation for oral or targeted delivery
For consortia, additional complexity includes:
- maintaining strain ratios
- preventing selective loss during processing
This is where many programmes fail. The biology works in fermentation but collapses in downstream. Elise Biopharma prevents that by designing downstream as an extension of the organism’s biology.
Formulation and Delivery
A defining feature of Microbiome Therapeutics CDMO Services is that formulation is not optional. It is central.
The organism must survive:
- processing
- storage
- transport
- administration
- passage through the body, including gastric conditions when relevant
We support:
- lyophilised formulations
- encapsulation strategies
- enteric protection
- stability optimisation
- CFU and functional dose consistency
- cold-chain or ambient strategies
- packaging aligned with viability
The formulation is part of the therapeutic mechanism. A viable strain that does not reach the target site is not a successful product.
Analytics and Quality Control
Analytics in a Microbiome Therapeutics CDMO environment must define a living system.
Our Microbiome Therapeutics CDMO Services include:
- strain identity by genomic sequencing
- genotype confirmation
- phenotypic characterisation
- CFU enumeration
- viability assays
- metabolic activity profiling
- potency or functional assays
- contamination testing
- stability studies
- passage stability
- consortium composition analysis
For engineered strains:
- edit verification
- stability of engineered pathways
For consortia:
- ratio control
- ecological stability
The analytical challenge is not just measuring presence. It is proving functional consistency of a living therapeutic.
GMP Manufacturing and Regulatory Alignment
Microbiome therapeutics are regulated as biological drugs in many jurisdictions.
That means the Microbiome Therapeutics CDMO must support:
- GMP manufacturing
- strain traceability
- documentation and batch records
- contamination control
- facility segregation where needed
- comparability across batches
- stability and shelf-life data
- regulatory-ready CMC packages
Elise Biopharma’s Microbiome Therapeutics CDMO Services are built to support clinical progression and regulatory engagement from early development onward.
Why This Platform Is Growing Rapidly
Microbiome therapeutics are expanding because they offer something fundamentally different:
- direct interaction with host biology
- metabolic intervention at the microbial level
- immune modulation
- potential for chronic disease treatment
- new approaches to oncology, GI disease, and metabolic disorders
But the promise only becomes real if the manufacturing works. That is the bottleneck. That is why this category is growing quickly. And that is why the right Microbiome Therapeutics CDMO matters so much.
10 Reasons Companies Choose Elise for Microbiome Therapeutics
True LBP focus
Built for therapeutics, not consumer products
Strict anaerobic capability
Controlled environments for oxygen-sensitive strains
Strain fidelity and genomic control
Identity and stability preserved across the lifecycle
Consortia engineering capability
Multi-strain systems handled with precision
Engineered microbe expertise
Synthetic biology integrated into LBP workflows
Viability-first process design
The organism remains functional, not just present
Advanced formulation strategies
Survival through delivery is engineered
Integrated analytics for living systems
Genotype, phenotype, and function all measured
Clinical and GMP readiness
Built for real therapeutic programmes
Deep microbiology and process insight
Scientific rigor matched to live biological complexity
Technical Context and Platform Evolution
Microbiome therapeutics emerged from a shift in understanding: microbial communities are not passive passengers in human biology, but active participants in health and disease. As sequencing technologies advanced and mechanistic links became clearer, the idea of using defined microbes as therapeutics moved from concept to reality.
Early efforts often resembled advanced probiotics. Modern programmes do not. They are increasingly precise, mechanism-driven, and engineered. They rely on defined strains, controlled manufacturing, and analytical frameworks that can support regulatory review.
This evolution has raised the bar for manufacturing. It is no longer enough to grow bacteria. The process must preserve identity, function, and stability while meeting pharmaceutical standards. That is a fundamentally different challenge from traditional fermentation.
At Elise Biopharma, that challenge is addressed directly. Development is structured, not exploratory. Manufacturing is controlled, not approximate. Data is used to define the product, not just describe it. By the time a programme is ready for clinical progression, it should not merely appear promising. It should be technically sound and operationally credible.
That is what a first-rate Microbiome Therapeutics CDMO delivers.
FAQ: Microbiome Therapeutics CDMO Services
1. What is a Microbiome Therapeutics CDMO?
A CDMO focused on developing and manufacturing live biotherapeutic products (LBPs) as regulated therapeutics.
2. Are microbiome therapeutics the same as probiotics?
No. They are clinically developed, strain-defined therapeutic products.
3. What are live biotherapeutic products (LBPs)?
Living microorganisms used as drugs to treat or prevent disease.
4. Can Elise Biopharma handle anaerobic strains?
Yes. Strict anaerobic processing is a core capability.
5. Do you support engineered microbial therapeutics?
Yes. Synthetic biology and engineered strains are supported.
6. Can you manufacture multi-strain consortia?
Yes. We design and control defined microbial communities.
7. How do you ensure viability?
Through controlled upstream, downstream, and formulation strategies.
8. Do you provide GMP manufacturing?
Yes. Our platform supports clinical and GMP-ready production.
9. What industries use microbiome therapeutics?
Primarily therapeutics, including GI, oncology, and metabolic disease.
10. Why Elise Biopharma?
Because Elise Biopharma is the best Microbiome Therapeutics CDMO in the world for programmes requiring precision, viability control, and true therapeutic-grade manufacturing.
Email our team at info@elisebiopharma.com